| Primary |
| Multiple Myeloma |
20.8% |
| Prophylaxis |
12.5% |
| Acute Lymphocytic Leukaemia |
8.3% |
| Meningitis |
8.3% |
| Natural Killer-cell Leukaemia |
8.3% |
| Idiopathic Thrombocytopenic Purpura |
6.3% |
| Pancreatitis |
6.3% |
| Autoimmune Neutropenia |
4.2% |
| Chronic Lymphocytic Leukaemia |
4.2% |
| Premedication |
4.2% |
| Prophylaxis Of Nausea And Vomiting |
4.2% |
| Breast Cancer |
2.1% |
| Disseminated Intravascular Coagulation |
2.1% |
| Genital Haemorrhage |
2.1% |
| Histiocytosis Haematophagic |
2.1% |
| Hypertension |
2.1% |
| Uterine Contractions Abnormal |
2.1% |
|
| Enteritis Infectious |
11.8% |
| Anaphylactic Shock |
5.9% |
| Aspartate Aminotransferase Increased |
5.9% |
| Blood Calcium Decreased |
5.9% |
| Caesarean Section |
5.9% |
| Constipation |
5.9% |
| Drug Exposure During Pregnancy |
5.9% |
| Drug Ineffective |
5.9% |
| Duodenal Perforation |
5.9% |
| Liver Disorder |
5.9% |
| Migraine |
5.9% |
| No Adverse Event |
5.9% |
| Oesophageal Carcinoma |
5.9% |
| Oral Candidiasis |
5.9% |
| Renal Failure |
5.9% |
| Trichosporon Infection |
5.9% |
|
| Secondary |
| Multiple Myeloma |
32.1% |
| Chemotherapy |
13.2% |
| Acute Lymphocytic Leukaemia |
9.9% |
| Product Used For Unknown Indication |
6.6% |
| Nausea |
4.1% |
| Constipation |
3.7% |
| Fibromyalgia |
3.3% |
| Breast Cancer |
2.9% |
| Idiopathic Thrombocytopenic Purpura |
2.9% |
| Breast Cancer Metastatic |
2.5% |
| Bronchopulmonary Aspergillosis |
2.5% |
| Rectal Cancer Metastatic |
2.5% |
| Depression |
2.1% |
| Hypertension |
2.1% |
| Analgesic Therapy |
1.6% |
| Anxiety |
1.6% |
| Colon Cancer Metastatic |
1.6% |
| Gastritis |
1.6% |
| Inflammation |
1.6% |
| Lung Adenocarcinoma |
1.6% |
|
| Renal Failure |
22.0% |
| Cold Sweat |
8.0% |
| Pain In Extremity |
6.0% |
| Zygomycosis |
6.0% |
| Back Pain |
4.0% |
| Bone Pain |
4.0% |
| Chronic Lymphocytic Leukaemia |
4.0% |
| Drug Ineffective |
4.0% |
| Dyspnoea |
4.0% |
| Gastric Ulcer Haemorrhage |
4.0% |
| Gastrointestinal Ulcer Haemorrhage |
4.0% |
| Haemorrhagic Stroke |
4.0% |
| Leukocytosis |
4.0% |
| Osteonecrosis |
4.0% |
| Paraesthesia |
4.0% |
| Renal Impairment |
4.0% |
| White Blood Cell Count Decreased |
4.0% |
| Adverse Drug Reaction |
2.0% |
| Anaphylactic Reaction |
2.0% |
| Aspartate Aminotransferase Increased |
2.0% |
|
| Concomitant |
| Premedication |
22.2% |
| Prophylaxis |
13.3% |
| Multiple Myeloma |
10.4% |
| Breast Cancer |
8.1% |
| Colorectal Cancer |
7.8% |
| Prophylaxis Of Nausea And Vomiting |
6.3% |
| Colon Cancer Metastatic |
4.3% |
| Product Used For Unknown Indication |
3.8% |
| Ovarian Cancer |
3.4% |
| Breast Cancer Metastatic |
2.8% |
| Pain |
2.5% |
| Drug Use For Unknown Indication |
2.4% |
| Acute Lymphocytic Leukaemia |
1.9% |
| Hypertension |
1.9% |
| Diabetes Mellitus |
1.8% |
| Non-small Cell Lung Cancer |
1.8% |
| Chronic Hepatitis C |
1.6% |
| Antibiotic Therapy |
1.4% |
| Colon Cancer |
1.3% |
| Gastric Cancer |
1.2% |
|
| Weight Decreased |
9.1% |
| Death |
7.3% |
| Interstitial Lung Disease |
7.3% |
| Pneumothorax |
7.3% |
| Vomiting |
6.4% |
| White Blood Cell Count Decreased |
6.4% |
| Stomatitis |
5.5% |
| Malaise |
4.5% |
| Oedema Peripheral |
4.5% |
| Pain |
4.5% |
| Restlessness |
4.5% |
| Septic Shock |
4.5% |
| Shock |
4.5% |
| Cardiac Failure |
3.6% |
| Cardiac Failure Congestive |
3.6% |
| Dyspnoea |
3.6% |
| Hypersensitivity |
3.6% |
| Platelet Count Decreased |
3.6% |
| Convulsion |
2.7% |
| Disease Progression |
2.7% |
|
